LIPO — Lipella Pharmaceuticals Share Price
Last trade - 00:00- $3.48m
- $1.37m
- $0.45m
- 32
- 18
- 19
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.69 | ||
| Price to Tang. Book | 1.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -188.75% | ||
| Return on Equity | -148.74% | ||
| Operating Margin | -1021.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.69 | 0.96 | 0.26 | 0.18 | 0.45 | 0.15 | n/a | -10.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 15th, 2005
- Public Since
- December 20th, 2022
- No. of Shareholders
- 15
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,605,636
- Address
- 400 N Lexington St Ste Ll103, PITTSBURGH, 15208
- Web
- https://lipella.com/
- Phone
- +1 4129010315
- Contact
- Chuck Harbey
- Auditors
- Urish (Popeck) & Company
Similar to LIPO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 21:49 UTC, shares in Lipella Pharmaceuticals are trading at $0.57. This share price information is delayed by 15 minutes.
Shares in Lipella Pharmaceuticals last closed at $0.57 and the price had moved by -71.74% over the past 365 days. In terms of relative price strength the Lipella Pharmaceuticals share price has underperformed the S&P500 Index by -77.51% over the past year.
The overall consensus recommendation for Lipella Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Lipella Pharmaceuticals does not currently pay a dividend.
Lipella Pharmaceuticals does not currently pay a dividend.
Lipella Pharmaceuticals does not currently pay a dividend.
To buy shares in Lipella Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.57, shares in Lipella Pharmaceuticals had a market capitalisation of $4.34m.
Here are the trading details for Lipella Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LIPO
Based on an overall assessment of its quality, value and momentum Lipella Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lipella Pharmaceuticals is $2.00. That is 250.88% above the last closing price of $0.57.
Analysts covering Lipella Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lipella Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -46.45%.
As of the last closing price of $0.57, shares in Lipella Pharmaceuticals were trading -44.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lipella Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Lipella Pharmaceuticals' directors